Skip to main content

Allowing today’s children and adolescents to become tomorrow’s adult role models

Our Paediatric Research Hub allows us to promote research in the fields of paediatrics and adolescence. In doing so, it highlights the centre’s vast expertise while uniting efforts and capabilities in order to undertake global change initiatives that allow us to achieve the objectives agreed upon by the entire community of professionals who participate in paediatric and adolescence research at the Vall d'Hebron Campus.

 

logo Hub recerca pediàtrica EN

The Hub in figures

30
30
Of all the VHIR’s groups participate in paediatric research
5
5
Research groups focusing exclusively on paediatrics
26
26
PIs focusing exclusively on paediatrics
353
353
Publications
3,205
3K
Impact factor (total)
8
8
Impact Factor (average)
58
58
% publications Q1
167
167
Ongoing paediatric clinical trials
71
71
Ongoing competitive paediatric projects
tecniques-micro-lab-53
From research to healthcare

Mission: To promote, develop and transfer the paediatric research work undertaken at Vall d'Hebron University Hospital. Through excellence in our research work, we improve the health and quality of life of children and adolescents.

Vision: We want Vall d'Hebron’s paediatric research work to become a global benchmark which has a positive impact on the health and quality of life of paediatric patients and society in general.

Strategic lines

Assaigs Clínics
Pediatric clinical trials

As leaders in research, Vall d'Hebron Research Institute are involved in many clinical trials to children and adolescents. In this list you will be able to consult the pediatric clinical trials in which they are working, as well as the phase in which it is and if there has active recruitment.

See clinical trials

Organization chart

Today

Related news

A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress.

Researchers at the VHIR have carried out a study showing that the ClC-5 protein regulates collagen levels through the β-catenin pathway and lysosomal degradation.

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

Do you want to collaborate with us?

With your help we can increase knowledge of the different parologies that affect children and adolescents, improve diagnosis and discover new therapeutic approaches that have an impact on the quality of life of patients and their families.

More information